At a Glance
- Company: ST Pharm Co., Ltd.
- Location: South Korea (ST Pharm); USA (client)
- Deal value: US$56m contract
- Focus area: Oligonucleotide API for metabolic disease
- Next steps: Scale-up manufacturing and delivery
What happened?
ST Pharm signed a US$56 million contract with an undisclosed US biotechnology company to manufacture active pharmaceutical ingredients (API) for an oligonucleotide-based treatment targeting metabolic diseases. The agreement covers process development through commercial supply.
Why does it matter?
Oligonucleotide therapies offer precise targeting for metabolic disorders like obesity and dyslipidaemia, but complex manufacturing limits supply. ST Pharm’s expertise in nucleic acid APIs fills critical gaps, supporting accelerated clinical timelines amid surging demand for genetic medicines.
Who’s behind it?
ST Pharm, a South Korean CDMO specialising in oligonucleotides, peptides and complex molecules, serves global biotechs with GMP facilities. The US client advances an oligo programme in metabolic disease, likely focusing on liver-targeted ASOs or siRNAs.
How was it achieved?
Deal leverages ST Pharm’s optimised oligo synthesis, purification and scale-up capabilities, ensuring high-purity API compliant with US/EU standards for injectable or subcutaneous delivery.
What’s next?
ST Pharm initiates technology transfer, process validation and GMP production, with milestones tied to clinical batches and commercial launch. Potential for repeat contracts as the client’s programme advances to phase 3/market.